Celcuity Inc (CELC)

$92.68 +6.68 (7.77%)
Market Cap 3.61B
Revenue (ttm) 0.00
Net Income (ttm) -111.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 2.24
Volume 1,312,000
Avg Vol 1,153,034
Day's Range N/A - N/A
Shares Out 42.43M
Stochastic %K 90%
Beta 0.72
Analysts Strong Sell
Price Target $82.50

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: 763 392 0767
Address:
16305 36th Avenue North, Suite 100, Minneapolis, United States
LarInvests
LarInvests Nov. 14 at 5:13 PM
$CELC truly feel blessed to be a long term holder here
1 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 3:56 PM
breakout buzz $CDTX $RVMD $APGE $OWLT $CELC all tapping fresh 52-week highs. biotech acting like it found an extra gear today. what’s driving the surge? full breakdown inside. https://stocksrunner.com/news/2025-11-14-52-week-high-breakout-stocks-to-watch-right-now
0 · Reply
Okadarlan
Okadarlan Nov. 14 at 3:48 PM
$CELC time to short this. @IjustTradeiT
1 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 5:49 PM
Craig-Hallum updates rating for Celcuity ( $CELC ) to Buy, target set at 96 → 108.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 4:00 PM
Stifel has adjusted their stance on Celcuity ( $CELC ), setting the rating to Buy with a target price of 68 → 115.
0 · Reply
widgeon7
widgeon7 Nov. 13 at 2:57 PM
$CELC CEO said last nite the expectation is for $2.5–3.0B peak revenue. That's a game changer. The buyout numbers shift hugely to the upside
0 · Reply
HappyStockholder
HappyStockholder Nov. 8 at 1:24 PM
$CELC I always get a kick out of people who post that it means something when Vanguard reports shares in 13F filings. Vanguard purchases shares via an algorithm for its index funds. It is not an active investor. Reports from active investors, such as Baker Bros. and Perceptive Advisors are far more meaningful. Looking forward to seeing all the reports, which are due by Nov. 14.
1 · Reply
LarInvests
LarInvests Nov. 7 at 3:23 PM
$CELC so many bullish 13Fs filed here today. Particularly Vanguard, added 23% to their position
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 4:51 PM
$CELC Share Price: $73.68 Contract Selected: Mar 20, 2026 $75 Calls Buy Zone: $10.71 – $13.23 Target Zone: $17.35 – $21.21 Potential Upside: 53% ROI Time to Expiration: 133 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
S_Franconi
S_Franconi Nov. 4 at 12:52 PM
$CELC MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025. https://api.quotemedia.com/supplement/news-story/?webmasterId=104291&qmodStoryID=8421415869367976
0 · Reply
Latest News on CELC
Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 8:01 PM EST - 1 day ago

Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 2 days ago

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Nov 5, 2025, 7:05 AM EST - 9 days ago

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:05 AM EST - 10 days ago

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results

Oct 21, 2025, 5:41 PM EDT - 24 days ago

Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results

Celcuity Inc. (CELC) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting Transcript

Oct 20, 2025, 5:05 PM EDT - 25 days ago

Celcuity Inc. (CELC) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting Transcript

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 25 days ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CRMD RANI RAPT

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Oct 18, 2025, 4:30 AM EDT - 27 days ago

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Oct 18, 2025, 4:30 AM EDT - 27 days ago

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Oct 18, 2025, 4:30 AM EDT - 27 days ago

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Celcuity: Blink And You Missed It

Oct 8, 2025, 11:22 AM EDT - 5 weeks ago

Celcuity: Blink And You Missed It

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Sep 22, 2025, 9:15 AM EDT - 7 weeks ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Sep 9, 2025, 4:01 PM EDT - 2 months ago

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 11:40 AM EDT - 3 months ago

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 3 months ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Aug 7, 2025, 7:05 AM EDT - 3 months ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Jul 30, 2025, 3:42 PM EDT - 3 months ago

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Jul 30, 2025, 6:30 AM EDT - 3 months ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Celcuity: What's Happening With CELC Stock?

Jul 29, 2025, 6:40 AM EDT - 3 months ago

Celcuity: What's Happening With CELC Stock?

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Jul 28, 2025, 4:02 PM EDT - 3 months ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Jul 28, 2025, 3:02 PM EDT - 3 months ago

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Jul 28, 2025, 7:49 AM EDT - 3 months ago

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Jul 28, 2025, 7:00 AM EDT - 3 months ago

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Jul 25, 2025, 4:05 PM EDT - 4 months ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Jul 24, 2025, 4:01 PM EDT - 4 months ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Jul 14, 2025, 7:05 AM EDT - 4 months ago

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Jun 30, 2025, 7:05 AM EDT - 4 months ago

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 21, 2025, 7:05 AM EDT - 6 months ago

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:36 PM EDT - 6 months ago

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:01 PM EDT - 6 months ago

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

May 7, 2025, 7:05 AM EDT - 6 months ago

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Apr 1, 2025, 7:05 AM EDT - 8 months ago

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:50 PM EDT - 8 months ago

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:01 PM EDT - 8 months ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Mar 24, 2025, 7:05 AM EDT - 8 months ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Feb 25, 2025, 7:05 AM EST - 9 months ago

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Feb 19, 2025, 6:24 PM EST - 9 months ago

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 7:05 AM EST - 1 year ago

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:42 PM EST - 1 year ago

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Nov 12, 2024, 7:05 AM EST - 1 year ago

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Nov 7, 2024, 7:05 AM EST - 1 year ago

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Aug 16, 2024, 3:50 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Aug 7, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Jul 5, 2024, 12:05 AM EDT - 1 year ago

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Celcuity To Participate in Jefferies Global Healthcare Conference

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Celcuity To Participate in Jefferies Global Healthcare Conference

Celcuity Announces Pricing of Underwritten Common Stock Offering

May 30, 2024, 7:36 AM EDT - 1 year ago

Celcuity Announces Pricing of Underwritten Common Stock Offering

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

May 30, 2024, 7:00 AM EDT - 1 year ago

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

LarInvests
LarInvests Nov. 14 at 5:13 PM
$CELC truly feel blessed to be a long term holder here
1 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 3:56 PM
breakout buzz $CDTX $RVMD $APGE $OWLT $CELC all tapping fresh 52-week highs. biotech acting like it found an extra gear today. what’s driving the surge? full breakdown inside. https://stocksrunner.com/news/2025-11-14-52-week-high-breakout-stocks-to-watch-right-now
0 · Reply
Okadarlan
Okadarlan Nov. 14 at 3:48 PM
$CELC time to short this. @IjustTradeiT
1 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 5:49 PM
Craig-Hallum updates rating for Celcuity ( $CELC ) to Buy, target set at 96 → 108.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 4:00 PM
Stifel has adjusted their stance on Celcuity ( $CELC ), setting the rating to Buy with a target price of 68 → 115.
0 · Reply
widgeon7
widgeon7 Nov. 13 at 2:57 PM
$CELC CEO said last nite the expectation is for $2.5–3.0B peak revenue. That's a game changer. The buyout numbers shift hugely to the upside
0 · Reply
HappyStockholder
HappyStockholder Nov. 8 at 1:24 PM
$CELC I always get a kick out of people who post that it means something when Vanguard reports shares in 13F filings. Vanguard purchases shares via an algorithm for its index funds. It is not an active investor. Reports from active investors, such as Baker Bros. and Perceptive Advisors are far more meaningful. Looking forward to seeing all the reports, which are due by Nov. 14.
1 · Reply
LarInvests
LarInvests Nov. 7 at 3:23 PM
$CELC so many bullish 13Fs filed here today. Particularly Vanguard, added 23% to their position
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 4:51 PM
$CELC Share Price: $73.68 Contract Selected: Mar 20, 2026 $75 Calls Buy Zone: $10.71 – $13.23 Target Zone: $17.35 – $21.21 Potential Upside: 53% ROI Time to Expiration: 133 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
S_Franconi
S_Franconi Nov. 4 at 12:52 PM
$CELC MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025. https://api.quotemedia.com/supplement/news-story/?webmasterId=104291&qmodStoryID=8421415869367976
0 · Reply
Godwins26
Godwins26 Nov. 3 at 5:07 PM
Watchlist today 😊 $FGL $FGI $RANI $CELC $JFU
0 · Reply
theflynews
theflynews Nov. 2 at 10:06 PM
Short Report: AST SpaceMobile bears return after violent squeeze - $CELC - https://thefly.com/permalinks/entry.php/CELCid4227496?1762120702
0 · Reply
widgeon7
widgeon7 Oct. 31 at 2:38 PM
$CELC Breaking out of Bollinger Band squeeze?
0 · Reply
LarInvests
LarInvests Oct. 30 at 7:36 PM
Portfolio green today amidst the blood everywhere else. Thank you $CELC
0 · Reply
BrianRix
BrianRix Oct. 27 at 5:31 PM
$CELC Why did I sell at 56? Foolish!
2 · Reply
LarInvests
LarInvests Oct. 27 at 2:30 PM
$CELC still holding. Up over 450% across two accounts. 💎🤲
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 23 at 11:38 AM
$CELC this was posted by an oncologist on x. thought it was a helpful diagram of the treatment landscape/updates at esmo 2025. i think gedatolisib could presumably also work in hr- bc, given its moa.
0 · Reply
XaviersLessons
XaviersLessons Oct. 23 at 5:52 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $NXT $HUBS $REGN $CELC Watchlist.
0 · Reply
MakeM0ney_444
MakeM0ney_444 Oct. 23 at 3:53 AM
$CELC does this have more room to run?
1 · Reply
topstockalerts
topstockalerts Oct. 22 at 7:17 PM
$CELC not bad today... 🙌
0 · Reply
HappyStockholder
HappyStockholder Oct. 22 at 7:02 PM
$CELC Above average volume.
0 · Reply
Brianum2011
Brianum2011 Oct. 22 at 6:58 PM
$CELC
0 · Reply